NCT02762123View on ClinicalTrials.gov

A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Rheumatoid Arthritis

Interventions

DRUG

BMS-986142 200mg

DRUG

BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)

DRUG

BMS-986142 350mg

Trial Locations (1)

78744

Ppd Development, Lp, Austin

Sponsors

Lead Sponsor

Bristol-Myers Squibb

All Listed Sponsors

lead

Bristol-Myers Squibb

INDUSTRY

NCT02762123 - A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates | Biotech Hunter | Biotech Hunter